| Literature DB >> 35392648 |
Nazanin Zahra Sepehri1, Mohammad Mahdi Parvizi1, Sepideh Habibzadeh2, Farhad Handjani1,3.
Abstract
Uremic pruritus is a frequent and prominent symptom in patients with advanced or end-stage renal disease. Lack of an effective treatment for kidney disease-associated pruritus often leads to many problems for these patients and makes it difficult to choose an appropriate treatment. The purpose of this evidence-based hypothesis is to share the scientific reasons and related mechanisms in order to claim that lettuce could be useful in the treatment of uremic pruritus. This hypothesis is based on studies related to lettuce and its anti-inflammatory, antioxidant, antidiabetic, sedative, hypnotic, nephroprotective, potassium balancing, and blood purification properties. As a result, we suggest that lettuce could be a good choice for improving and reducing uremic pruritus due to its certain characteristics. Although proof of this hypothesis requires further clinical trial studies, this hypothesis can nevertheless lead to formulating an appropriate therapy for uremic-induced pruritus. By conducting a molecular docking study, we investigated the interactions between nineteen natural bioactive components of lettuce (Lactuca sativa L.) and human kappa opioid receptors. The in silico docking studies revealed that most of the ligands showed better antipruritic efficacy than gabapentin. Gamma-tocopherol, delta-tocopherol, and campesterol demonstrated the highest binding affinities toward the target protein.Entities:
Year: 2022 PMID: 35392648 PMCID: PMC8983187 DOI: 10.1155/2022/4231854
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Docking results of the active components of Lactuca sativa L. with 4DJH receptor.
| Compound | Docking score (kcal/mol) | Number of H-bonds | Estimated inhibition constant, Ki ( | Amino acid residues forming H-bond with their length in Å | Hydrophobic interactions |
|---|---|---|---|---|---|
| Alanine | −3.24 | 3 | 4220 | Asp138 (A) H-donor (2.57) | — |
| Alpha-lactucerol | −9.66 | 2 | 0.083 | Thr111 (A) H-donor (3.21, 2.84) | Gln115, Val118, |
| Alpha-linolenic acid | −6.50 | 1 | 17.32 | Thr111 (A) H-acceptor (2.68) | Val230, Phe231, |
| Alpha-tocopherol | −10.84 | 1 | 0.011 | Lys227 (A) H-donor (2.63) | Gln115, Val118, |
| Arginine | −5.20 | 6 | 154.21 | Met142 (A) H-donor (3.81) | Ile290, Ile294 |
| Ascorbic acid | −4.61 | 4 | 416.13 | Asp138 (A) H-donor (2.86) | — |
| Aspartic acid | −2.33 | 4 | 19480 | Asp138 (A) H-donor (2.72) | — |
| Betaine | −2.77 | 1 | 9260 | Ile316 (A) H-donor (2.87) | — |
| Caffeic acid | −5.33 | 4 | 123.69 | His291 (A) H-donor (2.79) | Val230, Ile290, Ile294 |
| Campesterol | −11.24 | 1 | 0.005 | Lys227 (A) H-donor (2.58) | Gln115, Asp138, |
| Choline | −3.29 | 1 | 3900 | Ile316 (A) H-donor (2.78) | |
| Delta-tocopherol | −11.29 | 2 | 0.005 | Lys227 (A) H-donor (2.88) | Tyr139, lys227, |
| Gamma-tocopherol | −11.72 | 1 | 0.002 | Lys227 (A) H-donor (3.24) | Val108, Asp138, |
| Glutamic acid | −3.27 | 4 | 4040 | Asp138 (A) H-donor (2.63, 2.70, 2.90) | Ile290, Ile294 |
| Niacin | −3.76 | 1 | 1740 | His291 (A) H-donor (2.72) | Ile294 |
| Pantothenic acid | −3.99 | 4 | 1200 | Asp138 (A) H-donor (2.77, 2.89, 2.77) | Val108, Trp287, Ile290, Ile294, Tyr320 |
| Pyridoxine | −5.02 | 4 | 210.20 | Asp138 (A) H-donor (2.75, 2.62) | Val108 |
| Riboflavin | −7.93 | 3 | 1.54 | Tyr312 (A) H-donor (2.77, 3.01) | Trp287, Ile316, Tyr320 |
| Thiamine | −7.38 | 2 | 3.90 | Tyr320 (A) H-donor (2.87) | Val108, Thr111, |
| Gabapentin | −5.68 | 3 | 68.98 | Asp138 (A) H-donor (3.01, 2.54, 2.70) | Val230, Ile290, Ile294 |
| Cocrystal ligand (JDC) | −10.18 | 1 | 0.017 | Asp138 (A) H-donor (2.71) | Val108, Gln115, |
Figure 1Docking interactions of kappa opioid receptor, 4DJH, with compounds (a) gamma-tocopherol, (b) delta-tocopherol, (c) campesterol, and (d) thiamine. The ligands are represented in green color and hydrogen bonds in blue color.
Figure 2(a) Comparison of two bound conformations of JDC in the kappa opioid receptor's active site: the yellow model shows the crystal orientation, and the redocked result is shown as a green model (b). The key residues surround the structure of JDC in the active site of the kappa opioid receptor.
Pharmacokinetic properties of the bioactive compounds of Lactuca sativa L.
| Compound | MW (g/mol) | HBA | HBD | TPSA ( | MR | Log | Log | GI absorption |
|---|---|---|---|---|---|---|---|---|
| Alanine | 89.09 | 3 | 2 | 63.32 | 21.01 | 0.34 | 1.54 | High |
| Alpha-lactucerol | 426.72 | 1 | 1 | 20.23 | 135.14 | 4.67 | −8.24 | Low |
| Alpha-linolenic acid | 278.43 | 2 | 1 | 37.30 | 88.99 | 3.36 | −4.78 | High |
| Alpha-tocopherol | 430.71 | 2 | 1 | 29.46 | 139.27 | 6.04 | −8.6 | Low |
| Arginine | 174.20 | 4 | 4 | 127.72 | 44.54 | 0.27 | 2.05 | Low |
| Ascorbic acid | 176.12 | 6 | 4 | 107.22 | 35.12 | −0.31 | 0.23 | High |
| Aspartic acid | 133.10 | 5 | 3 | 100.62 | 27.59 | −0.09 | 1.98 | High |
| Betaine | 117.15 | 2 | 0 | 40.13 | 28.35 | −2.19 | −0.35 | Low |
| Caffeic acid | 180.16 | 4 | 3 | 77.76 | 47.16 | 0.97 | −1.89 | High |
| Campesterol | 400.68 | 1 | 1 | 20.23 | 128.42 | 4.97 | −7.54 | Low |
| Choline | 104.17 | 1 | 1 | 20.23 | 29.69 | −2.14 | −0.1 | Low |
| Delta-tocopherol | 402.65 | 2 | 1 | 29.46 | 129.34 | 5.44 | −7.98 | Low |
| Gamma-tocopherol | 416.68 | 2 | 1 | 29.46 | 134.31 | 5.16 | −8.29 | Low |
| Glutamic acid | 147.13 | 5 | 3 | 100.62 | 32.40 | 0.40 | 1.84 | High |
| Niacin | 123.11 | 3 | 1 | 50.19 | 31.20 | 0.86 | −1.26 | High |
| Pantothenic acid | 219.23 | 5 | 4 | 106.86 | 52.21 | 0.95 | −0.06 | High |
| Pyridoxine | 169.18 | 4 | 3 | 73.58 | 43.48 | 0.80 | −0.64 | High |
| Riboflavin | 376.36 | 8 | 5 | 161.56 | 96.99 | 1.63 | −1.31 | Low |
| Thiamine | 265.35 | 3 | 2 | 104.15 | 73.26 | −1.60 | −2.32 | High |
MW, molecular weight; HBA, number of H-bond acceptor; HBD, number of H-bond donor; TPSA, total polar surface area; MR, molar refractivity; log P, lipophilicity; log S, water solubility.
QSAR observation results obtained from the PASS Server for lettuce (Lactuca sativa L.) components.
| Compound | Kappa opioid receptor antagonist |
|---|---|
| Alanine | Yes |
| Alpha-lactucerol | Yes |
| Alpha-linolenic acid | Yes |
| Alpha-tocopherol | No |
| Arginine | Yes |
| Ascorbic acid | Yes |
| Aspartic acid | Yes |
| Betaine | Yes |
| Caffeic acid | Yes |
| Campesterol | No |
| Choline | (Result not found) |
| Delta-tocopherol | Yes |
| Gamma-tocopherol | Yes |
| Glutamic acid | Yes |
| Niacin | Yes |
| Pantothenic acid | Yes |
| Pyridoxine | Yes |
| Riboflavin | No |
| Thiamine | (Result not found) |
| Gabapentin | Yes |
PASS prediction of the standard drug and the nominated bioactive compounds of Lactuca sativa L.
| Compound | Pa | Pi | Activity |
|---|---|---|---|
| Alpha-lactucerol | 0.749 | 0.010 | Anti-inflammatory |
| 0.229 | 0.228 | Anti-inflammatory, ophthalmic | |
| 0.250 | 0.065 | Nonsteroidal anti-inflammatory agent | |
| 0.025 | 0.005 | Anti-inflammatory steroid | |
| 0.660 | 0.010 | Antipruritic | |
| 0.512 | 0.035 | Antipruritic, allergic | |
| 0.412 | 0.012 | Antipruritic, nonallergic | |
| 0.283 | 0.103 | Opioid kappa 3 receptor antagonist | |
|
| |||
| Alpha-tocopherol | 0.814 | 0.006 | Anti-inflammatory |
| 0.587 | 0.003 | Anti-inflammatory, ophthalmic | |
| 0.203 | 0.098 | Nonsteroidal anti-inflammatory agent | |
| 0.599 | 0.016 | Antipruritic | |
| 0.252 | 0.202 | Antipruritic, allergic | |
| 0.217 | 0.079 | Antipruritic, nonallergic | |
| 0.328 | 0.080 | Antiallergic | |
|
| |||
| Campesterol | 0.502 | 0.056 | Anti-inflammatory |
| 0.457 | 0.005 | Anti-inflammatory, ophthalmic | |
| 0.043 | 0.003 | Anti-inflammatory steroid | |
| 0.774 | 0.004 | Antipruritic | |
| 0.679 | 0.004 | Antipruritic, allergic | |
| 0.502 | 0.003 | Antipruritic, nonallergic | |
|
| |||
| Delta-tocopherol | 0.720 | 0.013 | Anti-inflammatory |
| 0.436 | 0.006 | Anti-inflammatory, ophthalmic | |
| 0.351 | 0.076 | Antipruritic | |
| 0.349 | 0.106 | Antipruritic, allergic | |
| 0.222 | 0.076 | Antipruritic, nonallergic | |
| 0.251 | 0.151 | Opioid kappa 3 receptor antagonist | |
|
| |||
| Gamma-tocopherol | 0.775 | 0.008 | Anti-inflammatory |
| 0.562 | 0.003 | Anti-inflammatory, ophthalmic | |
| 0.222 | 0.083 | Nonsteroidal anti-inflammatory agent | |
| 0.222 | 0.155 | Anti-inflammatory, intestinal | |
| 0.511 | 0.033 | Antipruritic | |
| 0.338 | 0.113 | Antipruritic, allergic | |
| 0.238 | 0.066 | Antipruritic, nonallergic | |
| 0.220 | 0.164 | Antiallergic | |
| 0.223 | 0.205 | Opioid kappa 3 receptor antagonist | |
|
| |||
| Gabapentin | 0.320 | 0.144 | Anti-inflammatory |
| 0.370 | 0.032 | Anti-inflammatory, intestinal | |
| 0.357 | 0.024 | Anti-inflammatory, ophthalmic | |
| 0.298 | 0.043 | Nonsteroidal anti-inflammatory agent | |
| 0.307 | 0.109 | Antipruritic | |
| 0.422 | 0.072 | Antipruritic, allergic | |
| 0.283 | 0.043 | Antipruritic, nonallergic | |
| 0.708 | 0.009 | Analgesic | |
| 0.317 | 0.027 | Analgesic stimulant | |
| 0.357 | 0.040 | Opioid kappa 3 receptor antagonist | |
|
| |||
| Cocrystal ligand (JDC) | 0.301 | 0.115 | Antipruritic |
| 0.306 | 0.078 | Opioid kappa 3 receptor antagonist | |